Prospective Validation of the Use of the Freund Clock Drawing Test to Screen for Cognitive Dysfunction in Cancer Patients Undergoing Comprehensive Geriatric Assessment (PROACTIVE)
A Comprehensive Geriatric Assessment (CGA) has become a fundamental aid in the evaluation and treatment planning of older cancer patients. Systematic reviews of trials of geriatric assessments have shown effectiveness when interventions are implemented. Although CGA is a fundamental tool in the care of the geriatric patient, the integration and application of this tool in oncologic practice are still in evolution. Cognition is one of the domains examined within a CGA. Studies have noted that up to 25% to 50% of older patients had cognitive abnormalities that warranted further evaluation. Cognitive dysfunctions can influence the ability to weigh the risks and benefits of cancer therapy, to comply with the suggested treatment plan, and to recognize the symptoms of toxicity that need medical attention. Recently, the Freund Clock Drawing Test (CDT) has been proposed as a quick and simple screening tool to assess cognitive dysfunction. A retrospective analysis on 105 cancer patients at the General Hospital Groeninge showed that a cut-off score of ≤ 4 for the CDT has a good AUC, sensitivity and specificity.
- To validate the Clock Drawing Test as a screening tool to identify elderly cancer patients in need of a more in-depth cognitive evaluation within a comprehensive geriatric assessment (CGA)
- Further registration of data in a database coupled to the Cancer Registry in the General Hospital Groeninge as set up by the PROGERCAN study
Elderly Cancer Patients
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prospective Validation of the Use of the Freund Clock Drawing Test (CDT) to Screen for Cognitive Dysfunction in Cancer Patients Undergoing Comprehensive Geriatric Assessment (CGA)|
- Validation of the Freund Clock Drawing Test, and its predefined cut-off of ≤ 4, as a screening tool to identify elderly cancer patients in need of a more in-depth cognitive evaluation with the Folstein MMSE within comprehensive geriatric assessment [ Time Frame: Baseline ]Validation of the Freund Clock Drawing Test by use of Receiver Operating Characteristic (ROC) analysis
- Further registration of data in a database coupled to the Cancer Registry in the General Hospital Groeninge as set up by the PROGERCAN study [ Time Frame: Baseline ]During the PROGERCAN study, a database was set up in which the results of the CGA were coupled to the data available in the Cancer Registry of the General Hospital Groeninge. In this project, we aim continue this registration.
- Evaluation of the Mini-Cog (Cognitive screening tool consisting of a clock drawing with 3-word recall test) when using the Freund CDT [ Time Frame: Baseline ]
- To determine the time-saving [ Time Frame: Baseline ]Determination of the time-saving when using the Freund Clock Drawing Test instead of the Folstein MMSE
- To compare the Freund scoring system with other scoring systems (such as Watson and colleagues), when using a predrawn circle [ Time Frame: Baseline ]
- To develop a tumour tissue database (bio bank) of elderly cancer patients, solely for scientific purposes [ Time Frame: Baseline ]
|Study Start Date:||November 2012|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Design: A prospective, observational, cohort study. All geriatric patients who are diagnosed with cancer will be screened by an oncology clinical nurse specialist or study collaborator with the G8 questionnaire. Patients who screen positive, will be refered to the multi-disciplinary onco-geriatric program where a member of the geriatric oncology team will implement a comprehensive geriatric evaluation under supervision of an oncologist and/or geriatrician, who will then formulate recommendations and might suggest referral to other health care providers.
Population: All consenting patients, aged ≥ 70, who are referred for anti-cancer treatment in the General Hospital Groeninge and who are in need of a CGA.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01749995
|General Hospital Groeninge, Cancer Center|
|Kortrijk, Belgium, 8500|